|
|
Africa: Daily HIV/Aids Report
 |
|
|||||||||
|
||||||||||
Kaisernetwork.org (Washington, DC)
8 May 2008
Posted to the web 8 May 2008
Politics and Policy
AIDS Orphan Advocates Call for Increased Community-Based Programs, Passage of PEPFAR Bill
Science & Medicine
Biotech Firm GeoVax Labs To Launch Phase II Trials of HIV Vaccine Candidate
Rapid HIV Tests Highly Effective in Preventing Mother-to-Child HIV Transmission in India, Study Finds
Global Challenges
New HIV Cases Increasing in Germany, Institute Says
Namibia To Launch Pilot HIV Testing, Counseling Project
HIV/AIDS Funding in Tanzania Expected to Total $476M, Government Report Says
Politics and Policy
AIDS Orphan Advocates Call for Increased Community-Based Programs, Passage of PEPFAR Bill
[May 08, 2008]
Advocacy groups on Wednesday during a briefing about the millions of children worldwide who have lost one or both parents to AIDS called for an increase in community-based programs to assist AIDS orphans, as well as the passage of legislation to reauthorize the President's Emergency Plan for AIDS Relief, CQ HealthBeat reports (Cooley, CQ HealthBeat, 5/7). The House last month voted to approve a bill (HR 5501) that would reauthorize PEPFAR at $50 billion over the next five years, among other measures. The Senate version, which also would allocate $50 billion over five years, passed the Foreign Relations Committee in March and is awaiting floor consideration (Kaiser Daily HIV/AIDS Report, 4/3).
Speakers at the briefing -- which was hosted by the groups Global Action for Children and Francois-Xavier Bagnoud -- said that community-based efforts in addition to increases in PEPFAR funding are necessary to address HIV/AIDS. FXB Founder Albina du Boisrouvray said that local initiatives are needed to prevent children from "drifting" into commercial sex work or becoming child soldiers, which she called "ills that we spend so many billions fighting downstream instead of preventing upstream."
Jim Yong Kim -- a professor of health, human rights and medicine at Harvard University -- said, "We have to take a hard look at how we're spending our money." He and other speakers called for family-centered approaches to addressing AIDS orphans, adding that institutional care often is associated with poor outcomes. "Your average American, when thinking of the orphan crisis, thinks either of adoption or orphanages," advocate Diana Aubourg Millner said. She and Kim said that they support programs that encourage family members and communities to care for orphans.
Kim also said that money should be given directly to communities instead of large international and often faith-based groups. He said that cash transfers given directly to impoverished families have increased school enrollment and attendance in Honduras, Mexico, South Africa and Zambia. In addition, Kim emphasized the role of PEPFAR funding in supporting and expanding such initiatives. "Nothing has made me prouder of being an American than watching what PEPFAR has done," he said (CQ HealthBeat, 5/7).
Link to this story.
Science & Medicine
Biotech Firm GeoVax Labs To Launch Phase II Trials of HIV Vaccine Candidate
[May 08, 2008]
|
The Atlanta-based biotechnology firm GeoVax Labs plans to launch Phase II clinical trials of its experimental HIV vaccine this summer, company officials recently announced, the Atlanta Journal-Constitution reports (Hendrick, Atlanta Journal-Constitution, 5/8).
GeoVax while in midstage development of its HIV vaccine candidate enrolled 140 people in four independent national trials. The firm is developing the experimental HIV vaccine in collaboration with Emory University, CDC and NIH. According to Emory officials, a prototype of the vaccine provided long-term protection against development of AIDS in nonhuman primate studies conducted more than three years ago at the Yerkes National Primate Research Center in Atlanta. NIH awarded the firm a $15 million grant in October 2007 to further its research and continue human clinical trials (Kaiser Daily HIV/AIDS Report, 10/1/07).
The vaccine is the only candidate among several under development that is "on the verge" of being moved to Phase II trials by the HIV Vaccine Trials Network, the Journal-Constitution reports.
| |||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
| Make allAfrica.com your home page | RSS Feed | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
| Top | Site Guide | Who We Are | Advertising | Search | Subscribe | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
| Questions or Comments? Contact us. Read our Privacy Statement. | |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
